Author contribution:
AM proposed using bortezomib and wrote the text, UP, IK, DF, DB and NK provided clinical care and data retrieval, EK provided plasma exchange, PA assayed ADAMTS13 activity and anti-ADAMTS 13 inhibitors titres, GN participated in discussion and provided valuable advices about paper final version.
References
  1. Joly BS, Stepanian A, Leblanc T, et al. Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy. Lancet Haematol . 2016;3(11):e537-e546. doi:10.1016/S2352-3026(16)30125-9
  2. Peyvandi F, Lavoretano S, Palla R, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica . 2008;93(2):232-239. doi:10.3324/haematol.11739
  3. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339(22):1578-1584. doi:10.1056/NEJM199811263392202
  4. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339(22):1585-1594. doi:10.1056/NEJM199811263392203
  5. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325(6):393-397. doi:10.1056/NEJM199108083250604
  6. Fakhouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood. 2005;106(6):1932-1937. doi:10.1182/blood-2005-03-0848
  7. Jestin M, Benhamou Y, Schelpe AS, et al. Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura. Blood . 2018;132(20):2143-2153. doi:10.1182/blood-2018-04-840090
  8. Scully M. Rituximab in the treatment of TTP. Hematology. 2012;17 Suppl 1:S22-S24. doi:10.1179/102453312X13336169155178
  9. Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med . 2019;380(4):335-346. doi:10.1056/NEJMoa1806311
  10. Jin M, Casper TC, Cataland SR, et al. Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. Br J Haematol . 2008;141(5):651-658. doi:10.1111/j.1365-2141.2008.07107.x
  11. Shortt J, Oh DH, Opat SS. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med. 2013;368(1):90-92.doi:10.1056/NEJMc1213206
  12. Patriquin CJ, Thomas MR, Dutt T, et al. Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura. Br J Haematol. 2016;173(5):779-785. doi:10.1111/bjh.13993
  13. Hernández Lorente E, Lluch García R, Monteagudo Santolaya E. Effectiveness of bortezomib in the treatment of thrombotic thrombocytopenic purpura: Case report. Efectividad del bortezomib en el tratamiento de la púrpura trombótica trombocitopénica: descripción de un caso. Med Clin (Barc). 2019;152(6):244-245. doi:10.1016/j.medcli.2018.06.002
  14. Mazepa MA, Raval JS, Moll S, Ma A, Park YA. Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol. 2014;164(6):900-902. doi:10.1111/bjh.12696
  15. van Balen T, Schreuder MF, de Jong H, van de Kar NC. Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib. Eur J Haematol . 2014;92(1):80-82. doi:10.1111/ejh.12206
Figure 1.
Therapies delivered and evolution of laboratory parameters of patient 1. Solid line indicates platelet counts, dash line depicts ADAMTS13 activity. PEX and arrows indicate plasma exchanges, R with white arrowheads indicate rituximab, M followed by circles indicate high-dose methylprednisolone, and B with black arrowheads indicate bortezomib.
Figure 2.
Therapies delivered and evolution of laboratory parameters of patient 1. Solid line indicates platelet counts, dash line depicts ADAMTS13 activity. PEX and arrows indicate plasma exchanges, R with white arrowheads indicate rituximab, M followed by circles indicate high-dose methylprednisolone, and B with black arrowheads indicate bortezomib.